Single-pill vs free-equivalent combination therapies for hypertension A meta-analysis of health care costs and adherence
This meta-analysis compares health care resource use costs, adherence, and persistence between groups of patients taking antihypertensives as single-pill combinations (SPCs) vs free-equivalent components (FEC) based on a structured review of published studies. The search yielded 12 retrospective database studies included in analyses. The mean difference in combined total annual all-cause and hypertension-related health care costs was $1357 (95% confidence interval [CI], $778–$1935) lower in favor of SPC than FEC groups. Adherence, measured as the mean difference in medication possession ratio, was estimated to be 8% higher for patients naive to prior antihypertensives and 14% higher for nonnaive SPC patients compared with corresponding FEC patients. Persistence in the SPC groups was twice as likely as the FEC groups (pooled risk ratio, 2.1; 95% CI, 1.1–4.1). Improved adherence and persistence may have contributed to the lower costs in the SPC groups via improved clinical outcomes.
Sherrill, E., Halpern, M., Khan, S., Zhang, J., & Panjabi, S. (2011). Single-pill vs free-equivalent combination therapies for hypertension: A meta-analysis of health care costs and adherence. Journal of Clinical Hypertension, 13(12), 898-909. DOI: 10.1111/j.1751-7176.2011.00550.x